Atossa Therapeutics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) announced its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Zacks reports.

Atossa Therapeutics Price Performance

NASDAQ ATOS traded down $0.01 on Tuesday, hitting $0.73. 100,420 shares of the company’s stock were exchanged, compared to its average volume of 1,017,699. The firm has a market cap of $92.34 million, a price-to-earnings ratio of -3.40 and a beta of 1.20. The firm’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $1.12. Atossa Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.31.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 12th.

Institutional Trading of Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE raised its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the quarter. Bank of America Corp DE owned 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the SEC. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.